Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymosin Alpha 1 in Resected Stage I NSCLC
NCT06598839Recruiting
- Start
- Jun 2024
- Primary completion
- Sep 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, open-label trial of thymosin alpha 1 in non-small cell lung cancer (NSCLC) (2 arms). Primary endpoint: Number of Circulating Tumor Cells. Started Jun 2024; status: recruiting.
02
Drugs
thymosin alpha 1
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06598839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06598839.